United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - mannitol - inhalation powder - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - mannitol - inhalation powder - 40mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

chiesi ltd - verapamil hydrochloride - modified-release tablet - 240mg

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - budesonide 3mg - modified release capsule - 3 mg - active: budesonide 3mg excipient: acetyl tributyl citrate ethylcellulose gelatin methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc simeticone sugar spheres triethyl citrate - entocort capsules are indicated for the induction of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - metyrapone 250mg;   - soft gelatin capsule - 250 mg - active: metyrapone 250mg   excipient: acetanisole ethyl hydroxybenzoate as the sodium salt ethyl vanillin gelatin glycerol   ink macrogol 400 macrogol 4000 purified water sodium propyl hydroxybenzoate titanium dioxide - therapeutic applications metopirone can be employed as supplementary therapy in conditions associated with overproduction of glucocorticoids and mineralocorticoids, particularly when causal treatment is not possible. cushing's syndrome, especially when related to adrenal tumours hyperaldosteronism, resistant oedema

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - salcatonin 100 iu/ml;  ;   - solution for injection - 100 iu/ml - active: salcatonin 100 iu/ml     excipient: glacial acetic acid nitrogen sodium acetate trihydrate sodium chloride water for injection - acute bone pain associated with hip arthroplasty osteolysis and osteoporotic vertebral compression fracture.

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - formoterol fumarate dihydrate, glycopyrronium, beclometasone dipropionate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

New Zealand - English - Medsafe (Medicines Safety Authority)

chiesi new zealand limited t/a emerge health - deferiprone 1000mg;   - film coated tablet - 1000 mg - active: deferiprone 1000mg   excipient: crospovidone hyprolose hypromellose macrogol 8000 magnesium stearate methylcellulose titanium dioxide - ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major who are unable to take desferrioxamine therapy or in whom desferrioxamine therapy has proven ineffective.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 100 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty 10 microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; hydrochloric acid - copd trimbow 100/6/10 is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid (ics) and a long-acting beta2-agonist (laba) or a combination of a laba and a long-acting muscarinic antagonist (lama). asthma trimbow 100/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Australia - English - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 1.6 g - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; hypromellose; colloidal anhydrous silica; magnesium stearate; macrogol 6000; methacrylic acid copolymer; triethyl citrate; glyceryl monostearate; polysorbate 80; sodium hydroxide; maize starch; iron oxide red; iron oxide yellow; monobasic potassium phosphate - asacol is indicated for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.